Immunovant (IMVT)

Healthcare · Biotechnology
$32.11 -3.43% on the day Market cap $5.9B 52-week range $15.95 to $45.42 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Immunovant's free cash flow was negative in fiscal 2026, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from IMVT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation3
Profitability0
Financial health9

Key numbers

P/E (trailing)—
P/E (forward)0.00x
Price / free cash flow—
EV / EBITDA—
Price / sales0.00x
Price / book5.96x
Revenue growth—
Operating margin—
Net margin—
Return on equity-73.2%
Dividend yield—
Debt / equity0.16x

Results from SEC filings

Fiscal years, from Immunovant's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20222023202420252026
Revenue—————
Net income-$157M-$211M-$259M-$414M-$506M
Free cash flow-$106M-$188M-$215M-$377M-$407M
EPS (diluted)-$1.43-$1.71-$1.88-$2.73-$2.77
Operating margin—————

Superinvestors who own IMVT

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Tom Steyer
Farallon Capital Management LLC
Added $224M1.0%Q2 2026
Joel Greenblatt
Gotham Asset Management
New position $1M0.00%Q2 2026
Cliff Asness
AQR Capital Management
New position $426,9900.0%Q2 2026

Insider buying

Open-market purchases by Immunovant's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of IMVT in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when IMVT trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Immunovant insiders buying the stock?

No open-market insider purchases of IMVT in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Immunovant?

3 of the superinvestors Investingly tracks hold IMVT in their latest 13F, including Tom Steyer, Joel Greenblatt, Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.